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ABSTRACT

Using the technology afforded by Winschel et al., cyclen-1, a high affinity, strong
complexation agent for 8-hydroxypyrene-1,3,6 trisulfonate and derivatives, a new
assay has been developed for fluorescently labeling proteins of interest (POIs).
Ligation of the endogenous ligand for nicotinic acetylcholine receptors (nAChRs),
acetylcholine, using click chemistry afforded the triazole derivative of an alkynylacylcholine (compound 1) with 8-azidopyrene-1,3,6 trisulfonate (compound 2).
Liposomes encapsulated with Rhodamine B were used to strengthen the initial
fluorophore response of compound 2, using an anchored form of cyclen-1 complex.
Using a palmitoyl tail as the lipophilic moiety for liposomal amplification, the
subsequent response has a fluorophore ratio of up to 1:1 million, compound
2:Rhodamine B molecules. in vitro assay using compound 2 and cyclen-1 anchored
liposomes with HEK-293 cells produced a positive binding response, allowing
brightly colored fluorescent images of nAChRs upon the cellular membrane. A control
for nAChR binding was performed using a co-culture of HEK-293 and endothelial cell
lines. Control experiments show compound 2 and liposomes weak binding
endothelial cells, however, this could be do to accumulation from another mechanism,
more work is necessary to prove whether or not this is correct.
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RATIONALE

Many fluorescent labeling technologies used today exhibit an affinity label in order to
attach itself, whether covalently, or through non-bonding interactions, to the subject of
interest. The attachment of fluorophores to various proteins and cell lines has led to
improved visualization and understanding of protein dynamics, interactions and more,
however, many of the techniques rely on one fluorophore per subject of interest. Even
using fluorophores with exceptional quantum yields and emission spectra, a one
molecule limit cannot detect proteins which are extremely low in abundance. A
technique with the ability to amplify the fluorescent response of a low expression
protein could improve the diagnosis and treatment of individuals, as precancerous
cells are thought to exhibit low levels of certain membrane proteins.
Within this document, we describe a new technique for the fluorescent labeling of
ligand gated ion channels and the subsequent amplification of the primary label using
an affinity based liposome. By covalent attachment of two molecules, a ligand and a
fluorophore, which bind to separate targets, we form a ‘heterosandwich’ compound
which allows two binding events to occur simultaneously. The two binding events are
1) the ligand (acetylcholine) binding to its associated receptor and 2) the fluorophore
(PTS) binding to a receptor-molecule (cyclen-1) which exhibits high binding affinity
for the fluorophore. Amplification is based on the anchoring of the receptor, cyclen-1,
into the bilayer of liposomes, with liposomes encapsulating a solution of fluorophore
(with differing emission properties) within the aqueous pore.
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Scheme. Depiction of the two molecules covalently linked, allowing two simultaneous binding events to
occur. The binding of cyclen-1 with PTS (green molecule), and acetylcholine (black molecule) binding
to an Acetylcholine Receptor protein.

Many new labeling technologies promote the use of fusion proteins to fluorescently
label the protein of interest (POI) by fusing a suicide enzyme to the POI by vector
technology. The suicide enzyme can then form a covalent bond with a ligandfluorophore conjugate. These techniques can exhibit extremely high binding constants
of the ligand to the suicide enzyme (HaloTag has a binding constant higher than that
of strepavidin/biotin).

To test the methodology of this cascade system, we have chosen to use nicotinic
acetylcholine receptors (nAChRs) as the POI, using the endogenous ligand
acetylcholine (ACh) as one half of the heterosandwich complex.

Scheme. Structure of Acetylcholine.
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The second half of the complex is a dye which binds with cyclen-1, a pyrene
trisulfonate (PTS).

Scheme. Pyrene trisulfonate dyes. Y=OH, HPTS; Y=NH2, APTS; Y=N3, AzPTS.

Azidopyrene trisulfonate (AzPTS) allows the use of click chemistry and can easily
provide the heterosandwich complex.

Conjugate of ACh and AzPTS, (AChPTS)
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This new molecule allows us to test the heterosandwich hypothesis in vitro and
provide us with feedback to establish this new methodology of labeling and
fluorescent amplification of ligand gated ion channels.

Scheme. Image depicting the cascade binding sequences between a Protein of Interest (blue, bright blue
active site), ligand-fluorophore derivative (green), and a liposome anchored with cyclen-1 (red). The
binding of AChPTS to AChR is labeled as 1. The binding of the liposome with a tethered cyclen-1
molecule is labeled as 2.
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CHAPTER ONE

Fluorescence Microscopy and Small Molecule probes developed
for biological assays

1.1 Introduction

Fluorescent molecules have become extremely powerful tools in the development of
potent labeling agents; various cell lines, membrane proteins, and tumors can be
tagged with fluorophores, visually detecting aspects of the biological milieu under
investigation.1 Some fluorescent molecules exhibit the ability to be specifically
quenched with another molecule or environmental change i.e. pH, small molecule
reactants (H2S), oxidoreductants and more.2 Fluorescent molecular tags were not
instantly realized with the discovery of the phenomena of fluorescence. Small
molecule tags were the first labels, antibodies were reacted with aromatic isocyanates
in solution and allowed to behave in its proper biological environment.3 One of the
first proteins found to auto fluoresce, Green Fluorescent Protein (GFP) were used on a
large scale in labeling methods, however, GFP can inhibit natural activity due to the
sterically demanding protein. The use of fluorophores has led to intriguing and
exceptional results in biological breakthroughs, extending knowledge to new bounds.
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Sometimes when fluorophores are used, an excess is afforded, saturating the
solution/environment, affecting outcome and lowering the signal to noise ratio. The
ability to quench fluorophores is possible, albeit, sometimes the quenching process can
affect the outcome i.e. oxidoreductants, detergents, nonspecific-low potency
quenchers. In this work we describe the ability to specifically and tightly bind a
fluorophore attached to an endogenous ligand for various assays, labeling, surface
chemistry, and the development of a new methodology for excisions/excisional
biopsies.

1.2 Fluorescence Microscopy

Fluorescence microscopy has early beginnings, with various unrelated
concepts coming together into what is now an exceptional and powerful instrument
and technique. George Stokes, of Cambridge University, is considered to be one of the
founders of fluorescent study, even coining the term “fluorescence” from the
properties of one of the compounds he studied, CaF2 (fluorite/fluorspar) which emitted
red light upon irradiation with blue light4. His various studies (during and after 1852)
also concluded a longer wavelength emission compared to the wavelength of
excitation.4
During the development of higher precision microscope objectives, a relationship
between the wavelength of light and the resolution was noticed, case in point, UV was
the new goal, lowering the wavelength enhances resolution. While experimenting with
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higher frequency excitations (blue & UV) the German scientist August Kohler noticed
‘autoluminescence' (fluorescence) of certain tissues. Two breakthroughs in
microscopy, cellular & molecular biology are two of the first staining assays
introduced: 1) In 1941, Albert Hewett Coons successfully labeled a protein with a
fluorescent dye, pneumococcal anti-serum with anthracene-isocyanate and fluorescein
dyes, respectively. 2) By fluorescently labeling a secondary antibody, and a naked
primary antibody, viral counterparts were identified in culture.3

The modern fluorescent microscope is based off the original design in the 60s, using a
dichromatic mirror to reflect the excitation beam 90° into the sample solution,
inducing fluorochrome emission. Dichromatic mirrors behave in a convenient way,
reflecting higher energy light (shorter wavelength) and are seemingly transparent to
longer wavelengths, providing, in spatial terms, an area for the detector related to the
emission lamp. The image formed is gathered from multiple luminous points, or disks,
of light, scattering light ubiquitously. The objective lens only captures a fragment of
all light shining, and is directly proportional to the objective’s aperture at the imaging
distance of the lens.
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Figure 1.1. Diagram of the inner workings of a fluorescent microscope

In order to capture a precision image, fluorochrome illumination is required to
use a powerful, long lasting beam of light. All excitation wavelengths of the sample
(fluorochrome) must also be accounted for and use of a proper lamp is necessary.
Modern microscopes use a small range of high power illuminators, mercury, metal
halide, and xenon lamps or lasers.

Fluorescence microscopy, as defined by name, uses fluorescence to image cells and
molecules. Fluorescence is the incidental emission of longer wavelength light from
shorter wavelength absorbed light. As light energy is absorbed by a fluorophore (light
emitting molecule), electrons rise to a high energy singlet state and any excess energy
is released as a lower energy photon than the corresponding excitatory photon.
Fluorescence lifetime is within the picosecond to nanosecond time scale of emission
(10-12 -10-9 sec), the long lifetime release of photons is known as phosphorescence, on
the order of hundredths of seconds (10-2 sec) which also consists of an intersystem
crossing of a singlet state electron to the triplet state. At the lowest energy state of a
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molecule, electrons are referred to be in the ground state, or S0. As electrons are
energized by incidental light, they move from S0 to S1, S2 and Sn (excited singlet
states). The emission of light compared to excitation wavelength from the fluorophore
is referred to as the Stokes Shift of the molecule, with larger shifts being preferable for
fluorescence microscopy as a low shift can induce large amounts of noise and hard to
decipher emission spectra.

Figure 1.2. The Stokes Shift phenomena, exaggerated for clarity and understanding

Organic molecules exhibit fluorescent properties from a conjugated pi system,
alternating double bonds or aromaticity is necessary for light emission. A general but
not hard follow rule is the larger a pi system, the more red-shifted a molecule’s
emission becomes, while smaller fluorescent molecules exhibit in the (closer to) blue
region.
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Fluorescence microscopy had humble beginnings, in the mid-nineteenth century, and
has become one of the most sophisticated and powerful molecular biology techniques
to date. Studying protein dynamics, transportation, labeling of disease and much more,
the techniques presented are just some of the state-of-the-art advancements among this
diverse area of cellular visualization.

1.3 Cellular Imaging Techniques using Fluorescent Molecules

The amount of progress in recent years has been astounding, with the advent of
nucleotide base pair driven systems (Fluorescent in situ Hybridization), modified
enzymes with suicidal tendencies, forming stable covalent bonds with a specialized
ligand (HaloTag, SNAPtag, CLIPtag), and a reaction assisted fluorophore quench (βLactamase tag).5,6,7,8,9,10,11 Of these, some are vector based imaging techniques,
requiring the use of transfection of the wild type polypeptide with a fusion gene.
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1.4 Fluorescent tagging technologies

HaloTag:

HaloTag cell imaging technology is a modified form of haloalkane Dehalogenase
(DhaA), which hydrolyzes alkyl halides into alcohols and halide anions
respectively.5,6,7 A mutant form of DhaA creates a ‘locked’ covalent ester linkage
between the nucleophilic Asp 106 residue and the haloalkane ‘tag’. This mutant form
of DhaA replaces the WT amino acid of His272 to Phe272. As phenylalanine is a
neutral amino acid, the hydrogen bonding/basic system created for enzymatic
hydrolysis is disrupted, converting the enzyme into a high affinity covalent(suicide)
partner from it’s natural function of enzymatic hydrolysis of alkyl halides.

Figure 1.3. DhaA enzymatic activity, WT (above), suicide enzyme (left)
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Above, the wild type DhaA enzyme can perform its proper function of cleavage of the
aspartate ester by the His272 gated base. In the image to the left, notice Phe272
substitution. In this instance, water can not be deprotonated as base shuffling is
inhibited.

The haloalkane must be hydrophobic enough and long enough to fit into the binding
pocket of DhaA for covalent bond formation to occur, which was found to be a sixcarbon chain with the terminal ζ-C affording the electrophile.

R
Figure 1.4. HaloTag reactive substrate

SNAP-tag:
SNAP-tag technology is a mutant protein based on the DNA repair protein, O6alkylguanine-DNA alkyltransferase. The protein reacts specifically and quickly with
benzylguanine (BG) derivatives, forming a thioether and releasing guanine in the
process.8,9 To visualize a protein of interest, an expression vector is used to insert the
gene of interest into a polypeptide gene containing a high affinity labeling site. This
creates a fusion protein, the protein with the markable polypeptide on either the N- or
C-terminus, dependent on protein of interest binding site and interactions, etc. This
technique of polypeptide transfection is superior to fluorescent protein (FP)
transfection, such as green fluorescent protein (GFP), as synthetic fluorophores which
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bind to the polypeptide tag are paramount compared to natural peptide fluorophores.
SNAP-tag was developed on the premise of the O6-alkylguanine-DNA enzyme,
hAGT’s low specificity, including the binding of O6-benzylguanine, therefore,
provides a a modular core for affinity labeling.9

SNAP-tag has led to the development of another high affinity fusion protein,
based on reaction of benzylcytosine derivatives as opposed to benzylguanines, known
as CLIP-tag. This suicide enzyme can be used in conjunction with SNAP-tag to label
to different POIs simultaneously. This tandem fluorescent labeling has proven to be a
powerful technology for investigating protein-protein interactions.

β-Lactamase labeling:

β-Lactamase tag uses a similar approach as HaloTag and SNAPtag, transfection of a
polypeptide, in this case, a β-Lactamase, and an appropriate tag (ligand) which
covalently bonds to a fluorophore.10 The difference between the Halo and SNAP tags
compared to β-Lactamase is the use of bacterial proteins and ligands, as β-Lactamases
are not encoded within the human body, while Halo-tag and SNAPtag are modified
versions of human proteins.

Mizukami et al. evolved the approach to use fluorogenic β-lactam molecules as well,
fluorescently quenched molecules covalently attached to a β-lactam, a family of
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cephalosporins. Cephalosporins are appropriate to use for the fluorogenic approach as
a pi-system connects the β-lactam, forcing a resonant structure towards a fluorophore
and leaving group.10

Figure 1.5. β-lactamase quenching scheme

Fusion proteins as described above, HaloTag, SNAPtag, and β-Lactamase tag, provide
bio-orthogonality, high yields, and a variety of molecular tags, supplying a repertoire
of biological capability not known before.

Live cell imaging is a valuable technique which offers the immediate appointment of
use of the fluorescent molecule. Cell lines which exhibit similar properties to those
which are either difficult to culture, or obtain, can be studied more efficiently. nAChR
expressing HEK-293 cells were grown and assayed with the dye to distinguish the
molecule’s binding properties in vitro.
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Fluorescent in situ Hybridization:
Fluorescent in situ Hybridization (FISH), a labeling technique which detects the
presence, or absence, of a specific DNA sequence in a particular chromosome.11 A
probe is labeled with an affinity tag, such as biotin, and can be purified with
antibodies, determining whether or not the sequence is present. The high specificity of
FISH comes from the inherent binding of complementary sequences, allowing the
detection of not one DNA but many RNA targets as well (mRNA, miRNA, lncRNA
and more). FISH has been used in many different disciplines, genetic counseling,
medicine, species identification, as well as the identification of chromosomal mutation
and differentiation (genetic diagnostics). Before the advent of FISH, ISH was known,
using radiolabeled nucleotides, yet too many drawbacks were noticed with disposal,
safety, and cost. Probe sequences are synthesized through gene fragmentation of
whole sequences through in vitro nick translation with DNase. The genetic sequence is
‘nicked’ with DNase, a nucleotide is removed by 5’ exonuclease activity and are
replaced with dNTPs added into solution, some of which are biotinylated, DNA
polymerase closes the nick with the new NTP and offers a newly tagged gene product.
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CHAPTER TWO

Nicotinic Acetylcholine Receptors
2.1 Introduction
Nicotinic acetylcholine receptors (nAChRs) are widespread in organisms, present in
both the peripheral and central nervous systems and neuromuscular junctions.(15-29)
The receptors in the brain are some of the most important proteins in life and proper
health, dysfunction can lead to cognitive impairment, dementia, and radical
neurological discontinuity.(15-31) Diseases associate with the receptor include
Alzheimer’s Disease, Parkinson’s, schizophrenia, muscular dystrophy, epilepsy,
autism, nicotine addiction and many more.18,19,22,24,27,28,31
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Bakota, ’09; Wu, ’11; Itier, ’01; Sato, ’10; Wallace, ’13;
Young, ’13;
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Xu, ’12; Lombardo, ’14; Dineley, ’15;

Acetylcholine is the most studied endogenous substance, its inherent importance
within the mammalian system as a neurotransmitter dictates rigorous
investigation.15,16,19,21,23,25,31 Acetylcholine is released throughout the nervous systems,
by both pre and post-ganglionic fibers of the parasympathetic and the somatic nervous
systems. Neurons which release acetylcholine are known as cholinergic neurons. Two
natural alkaloids, muscarine and nicotine, further order the receptors through the
binding affinity of said molecules to the receptor. Receptors which bind muscarine
predominantly, at a lower concentration, are known as muscarinic acetylcholine

Commented [3]:
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receptors (mAChRs), nicotinic acetylcholine receptors (nAChRs) bind nicotine
preferentially.20

Figure 2.1. Structure of Acetylcholine

A nAChR was the first isolated and purified neuroreceptor in its active form, from the
torpedo stingray.26,32 nAChR is a pentameric transmembrane protein made up of a

Commented [4]:
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variety of 16 subunits, either homomeric (α only) or heteromeric pentamers of α, β, �,
ε, and δ subunits.20,33,34,35 The ε subunit is however only found in growing

Commented [5]:
Papke, ’14;

(embryonic) neuromuscular junctions, when mature, is replaced with the � subunit.
Heteromeric pentamers can exist as binary, trinary, and quaternary complexes, up to
four variable subunits forming one protein.16,20,34-36 Each subtype is genetically
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controlled and possesses its own affinity for acetylcholine and agonists/antagonists as
well as functionality.

Molecules which behave similarly to acetylcholine, which stimulate the nervous
system, are known as ‘cholinomimetic agents’.15,18,20 This class of compounds has the
ability to bind agonistically to the receptor, performing the same function as
acetylcholine, or the ability to inhibit such enzymes which destroy acetylcholine
enzymatically through acetylcholinesterase (AChE).37
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Subtypes of nAChRs consist of the following: neuromuscular, ganglionic neuronal,
central neuronal, and α7.15,17-19,20,23,25,,29,38 Pentameric subunits bind together in a
transmembrane fashion, with an amphipathic center which creates a hydrophilic pore
that can be opened and closed, allowing cations to cross the membrane.16,20,34-36
Binding of acetylcholine occurs on the extracellular matrix side of the protein, two
binding sites per protein, with sites located on the α subunits and the interface of α�
and αδ. All 16 subunit types consist of four moieties; 1) ~200 aa N-terminal
extracellular domain; 2) three transmembrane domains; 3) a non-conserved
cytoplasmic loop; and 4) C-terminal extracellular sequence of variable
sequence/length.16,34,35,39,40
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As nAChRs are pentameric and guided to open or close by the ligand acetylcholine,
affording passage of selective cations (Ca2+) through the membrane, nAChRs are a

Commented [9]:
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part of the pentameric ligand gated ion channel (pLGICs), the Cys Loop
Superfamily.24,,34,36,41,42 This family of ion channels play a large role in cellular
communication and are highly conserved throughout species. Along with nAChRs, the
Cys Loop superfamily includes 5-hydroxytryptamine receptors, �-aminobutyric acid
(GABAA&C) receptors, and Glycine (Gly) receptors. Cys Loop is derived from the
conserved fifteen amino acid sequence with the first and fifteenth amino acid forming
a disulfide bridge. This structure is shared by all members of the Cys Loop
superfamily.33-36,39,40
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Fast synaptic transmission relays information to nearby neurons quickly, releasing up
to 3 million acetylcholine molecules in one transmission. nAChRs are believed to play
a large role in many neurological diseases, including Alzheimer’s disease (AD),
Parkinson’s, amyotrophic lateral sclerosis (ALS/Lou Gehrig’s disease), epilepsy, and
schizophrenia among others.18,19,22,24,27,28,31
Nicotine, the stimulant in tobacco, is known to desensitize nAChRs and promote
addiction.

2.2 Binding site of nAChRs

The receptor proteins can exist in a multitude of conformational states that are ligand
dependent. From closed, being the most stable form, not allowing the passage of
calcium ions, open, where a ligand binds to the receptor and causes a mechanical
transformation allowing the opening of the pore, to the desensitized state, open or
closed, this occurs more often with more than one acetylcholine bound on a
protein.16,35,36,40

nAChRs contain two active binding sites which work in pseudo-tandem, one molecule
of ACh provides ample opportunity for the pore to open. When two (both) sites
interact with the neurotransmitter, a dramatic increase of ion pore opening occurs.
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Figure 2.2. nAChR (blue) with receptor (orange T-shape) bound to ACh (green shape), Ca2+ (pink
spheres) flux across membrane (gray)

The neuromuscular junction, where some nAChRs are located, is the convergence of
the musculature to the nervous system, stimulating and transferring information to and
from the brain and skeletal muscle.17,21,23

The binding of acetylcholine and agonists in the active site, the subunit interface, is
known to be attributed to six loops, A-F, which contain many highly conserved
aromatic residues as tyrosine and tryptophan. Loops A-C are contained within the
‘principal’ side of the active site, on one subunit. The remaining loops, D-F are on the
complementary side, completing the interfacial binding site.43

Trp143 (of loop B) affords stabilization of quaternary ammoniums and protonated
tertiary amines in the binding pocket by a cation-π interaction. Aromatic moieties of
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nAChRs agonists and antagonists generally increase the affinity of the ligand due to πstacking, affording possible therapeutic agents.

All Cys loop endogenous ligands possess a cationic ammonium moiety, whether a
quaternary amine (acetylcholine), or protonated primary amine (5hydroxytryptamine). The stabilization of the cationic molecules are highly conserved
throughout the Cys Loop superfamily, offering cation-π interactions with aromatic
residues, phenylalanine, tryptophan, and tyrosine.

Figure 2.3. Close up of nAChR binding site. Imperative binding moieties are colored.
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Loop C is known to have a significant conformational change upon binding, of either
agonist or antagonist. As agonists bind to the active site, loop C “fully contracts”,
while peptide inhibitors afford loop C a “fully extended conformation” and non
peptide inhibitors release a transitional conformation. This C loop movement can be as
much as 11Å determined by either agonistic or antagonistic binding.43

In the unbound AChR form, Loop C is above/over the the ligand binding site, and is
close in space to the extracellular loop (ECL), a short sequence between
transmembranes 2 & 3. Agonist binding leads to a wave of changes throughout the
protein, moving Loop C closer down to the ligand and the extracellular loop is
perturbed, allowing the ion channel to form.35,43

Water is also used as a stabilizer of the ligand in the binding pocket, using AChBP as
a structural homologue and more easily characterized, assisting in H-bonding of
various agonists including nicotine, varenicline, and lobeline.43

2.3 Acetylcholine Esterase
Acetylcholine esterase (AChE) is a serine hydrolase which inhibits acetylcholine
neurotransmitter action by hydrolyzing the molecule into choline and acetate.
Expressed in cholinergic neurons, its role is to stop transmission of chemical signals.
Acetylcholine is synthesized from acetyl CoA and choline. After synaptic vesicle
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delivery to the synaptic cleft, the molecule either binds to its receptor then is
enzymatically destroyed or is destroyed before receptor binding by the enzyme
acetylcholine esterase.37

Scheme 2.1. Reaction of Acetylcholine with ACh Esterase

The enzymatic function is known as the catalytic triad of serine, histidine and
glutamate.35,37 Glutamate-histidine acts as an anionic acid-base for serine which
nucleophilically attacks the carbonyl of acetylcholine. Backbone glycine N-H protons
are thought to stabilize the acetyl group transition state through hydrogen bonding.
Catalytic activity is restored through another catalytic triad mechanism, this time using
water as the nucleophile, hydrolyzing serine acetate.

Acetylcholine is synthesized in the body by cholinergic neurons, acetyl-CoA transfers
an acetyl group to choline by choline acetyltransferase. A large portion of choline used
for synthesis of acetylcholine comes from the recycling of choline from the
decomposition of synaptic acetylcholine by AChE. Choline itself can be synthesized
from serine through Serine Decarboxylase, S-Adenosyl methionine (methyl donor)
and Choline N-methyl transferase (three times), and Choline Acetyltransferase
(ChAT) in conjunction with Acetyl-S-CoA.
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Brain nAChRs consist mainly of the heterolog α4β2 with stoichiometries of 2:3 and 3:2
respectively, and the homolog α7, while muscle nAChRs consist of various subunits
and ratios.29,38,44 Neural acetylcholine receptors are known to be associated with a
variety of mental illness including depression, of which, α4β2 is targeted in drug
development and study. Hyperactivity of the cholinergic system relative to the
adrenergic system can lead to depression, as the drug physostigmine, an acetylcholine
esterase inhibitor, produces depressive symptoms in test subjects. As with AChE
inhibitors, depressive symptoms occur from a build up of ACh at the synapse which
leads to a long lasting desensitized state of the ion channel, allowing the unregulated
passage of Na+, K+, and Ca2+.

2.4 The Neuromuscular Junction

The parasympathetic nervous system (PNS) relays information from the central
nervous system (CNS) in the brain to the body using nerves in the muscle, limbs, and
organs. The PNS is much more easily prone to physical and toxic harm comparatively
to CNS as CNS is protected by bone, skull and spinal cord, and chemically by the
blood-brain barrier (BBB).17,21,25 The PNS is split into two classified systems, the
somatic and autonomic nervous systems, control of voluntary skeletal muscle control
and “involuntary” control of organs and bodily functions, respectively. The CNS is the
part of the nervous system which constitutes the brain and spinal cord, coordinating
information gathered from the peripheral nervous system to impact and direct action
within the body.27
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The neuromuscular junction is the flux of chemical information connecting the
nervous and muscular systems. Synapses between muscle fibers and efferent nerve
cells release calcium in a process known as the excitation-contraction coupling of
skeletal muscle. This leads to a chemical depolarization and ultimately, muscle
contraction.23,31,42
Action potentials, or nerve impulses, occur when voltage gated ion channels open
from a change in membrane potential, “firing” in sequence along the neuron, allowing
a large flux of sodium ions into the cell. The electrochemical gradient changes and in
doing so produces a larger electric current through the cellular membrane, after which,
the ion channels swiftly close. Potassium channels then open and flow out of the cell,
returning the cell to its resting electrochemical gradient.

When an action potential reaches the motor nerve terminal, ACh is released from
synaptic vesicles into the synaptic cleft; synaptic vesicles containing ACh are ~100
nm in diameter and fuse with the cellular membrane, thus releasing the
molecule.19,21,25 The neurotransmitters diffuse to the postsynaptic neuron and bind
with acetylcholine receptors, completing the chemical message. Acetylcholine travels
about 100 nm from where the vesicle fuses with the cellular membrane and releases
the neurotransmitter, to the ACh receptor on the targeted cell.
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CHAPTER THREE

Cyclen-Pyrene technology
3.1 Introduction

A selective, high affinity supramolecular complex, cyclen-1, was developed in 2005
by Winschel et al. to bind the fluorophore pH-sensitive dye,

8-

hydroxypyrene-1,3,6-trisulfonate (HPTS or pyranine). Using a combination of factors
including H-bonding, π-stacking of aromatic cores, enthalpy, and sodium ion chelation
between esters, cyclen-1 exhudes a high affinity and selectivity for HPTS along with
the others in the anionic dye series, 8-aminopyrene-1,3,6-trisulfonate (APTS), and
pyrene tetrasulfonate (PTA), which are non-functionalized members of the Cascade
Blue series of water soluble, non-toxic dyes.

3.2 Cyclen Receptor

Cyclen-1 is a strategically synthesized derivative of the cyclen core molecule. The
suggested mode of binding is a chelation-type system where the pyrene molecule fills
the space between the four arms, with the aromatic moieties π-stacking with the
pyrene core.45 The palmitoyl side chain delivers an extra feature, the ability to anchor
cyclen into the lipophilic membrane, while the toluidinyl moiety of cyclen provides
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the molecule with a variety of possible functionalities. Through the manipulation of
this species we are able to selectively target a receptor and amplify it’s fluorescent
response. With this methodology we can move on to more selective agonists and
competitive antagonists of nicotinic acetylcholine receptors in order to develop a novel
and potent fluorescent labeling mechanism for the attenuation of nicotinically derived
maladies. As this new methodology is hoping to transform excisional biopsies and
operations, the potential to visibly label problematic receptors is of great use.

Figure 3.1. Cyclen-1 receptor

Cyclen-1 is a promising molecule used in highly specific, non-covalent binding of a
fluorescent dye series, the pyrene trisulfonates/Cascade Blue series (and pyrene
tetrasulfonate). The dyes exhibit high quantum yield, absorptivity, water solubility,
and little/no toxicity.1 Since the affinity and binding is not based upon covalent bonds,
and the complexation necessitates conditions containing protic solvents, a simple rinse
with aprotic solvent breaks the complex, releasing the pyrene based dye into solution.
Cyclen-1 HPTS complexation is afforded due to a variety of moiety factors, including
the esters at the ‘base’ of the cyclen core, which are thought to chelate a sodium ion in
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solution, while a sulfonate of HPTS allows further stabilization due to ionic
interactions. π-stacking of the toluidinyl (cyclen-1) & napthyl (cyclen-2) moieties
provides electron density into the severely electron withdrawn pyrene core. Protic
solvents are necessary for binding to occur, while aprotic solvents rupture the
association, freeing the two molecules into solution.

Even though cyclen-1 exhibits low solubility, attachment of a ‘support’ moiety is
usually preferential anyway, rendering its aqueous characteristics minimal, just as
used in strepavidin-biotin complexations, usually one or both are covalently bonded to
another molecule for a particular study, foregoing the premise of unfortunate
properties. To showcase the point, 1% cyclen-2 anchored liposomes are extremely
stable and bind HPTS derivatives just as the naked affinity reagent.

3.3 Cascade Blue derivatives

This series of blue fluorescing, water soluble, highly anionic dyes exhibit high
extinction coefficients (~2.5 x104 M-1 s-1) and a ~20-100 nm Stokes Shift. Cascade blue
derivatives have been used as biologically orthogonal fluorophores for over two
decades.1 With great fluorogenic properties as described before i.e., quantum yield,
absorptivity, and aqueous solubility, the dyes can be used in a multitude of techniques
and assays. The cascade series also exhibits membrane impermeability due to the high
anionic character from the three sulfonate moieties.
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Figure 3.2. Pyrene trisulfonates. left to right: HPTS, APTS, AzPTS

Since the pyrene derivatives are bioorthogonal, in vivo and in vitro assays can be
performed readily, with the exception of a recently published article detailing the
complexation of HPTS and the central nervous stimulant, caffeine.46 Which would
require the patient to refrain from consuming caffeine pre-surgery if a cyclen-pyrene
tech excision methodology is used.
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CHAPTER FOUR

Liposomes
4.1 Introduction
Liposomes, or unilamellar vesicles, are spherical constructs of amphipathic molecules,
usually phospholipids. Consisting of a lipid bilayer, the polar heads of the molecules
are hydrophilic and form interactions with water, while the hydrophobic tails coalesce
together. As it consists of a bilayer, they contain a cavity of water on the interior.
Forming a model of the lipid bilayer was the initial suggestion, when they were
discovered in 1965, Bangham et al.47 However, throughout the years, liposomes have
gained attention as highly efficient, versatile, stealth drug delivery vehicles, a modern
day inverse biomimetic trojan horse.48-52 Liposomes are not only used in medicine,
and have been developed and studied in a diverse array. Bioengineering has seen
improvements with the use of the protective phospholipid bilayer, delivering genetic
material into new species and cells for the introduction and use in a host.14,48
As one of the highest occurring phospholipids in the animal body membrane,
phosphatidylcholine (PC) is an obvious choice for vesicle production and bioassays.
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Figure 4.1. Phosphatidylcholine

Liposomes, as synthetic constructs from commercially available biomolecules, have
easily controlled properties: particle size, composition, encapsulated media,
membranous targeting molecules, etc.

Lamellar vesicles are first formed through the hydration of amphipathic molecules.
After hydration, formation of bilayers produces multilamellar vesicles (MLVs),
essentially, liposomes within liposomes of various sizes. For more uniform size and a
higher entrapment ratio, the method of extrusion or sonication can be employed.
Extrusion uses pressure to force MLVs through a porous membrane to become a
certain size, by rupturing larger MLVs, they are forced into a physically confined
space and rip apart, re-coalescing on the other side of the membrane into smaller
vesicles, while sonication affords 68nm unilamellar vesicles, also known as small
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unilamellar vesicles (SUVs) <100 nm, large unilamellar vesicles range from >100 nm
to ~3μm.

Figure 4.2. Possible liposomal formulations and drug uptake capabilities.

4.2 Liposomes as vehicles

Liposomes exhibit various advantages as drug carriers. Degradation resistance is
inherent as the drug is trapped within an impermeable membrane, the bilayer and
aqueous core are safe from biological conditions and potential molecular threats. As
leakage is extremely slow due to poor diffusion, (pro)drugs and various molecules
have longer half-lives, as do viral and genetic materials.14,51 Due to the higher stability
of nucleotides, liposomes have also gained attention in the delivery of gene therapy
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and vaccines. The amphipathic character of liposomes allows the delivery of polar and
non polar molecules alike. Nonpolar molecules can exist within the lipid bilayer while
polar molecules are solvated by the interior aqueous core. Since liposomes are made
of biomolecules, they are preferential to many other types of diagnostic and
therapeutic vehicles, such as: colloidal gold, nanoparticles, quantum dots, dendrimers,
metallic nanoshells, micelles, nanospheres, and nanocapsules.55,56 Many of these
systems are inherently toxic and or toxic from accumulation/aggregation.

An early liposomal development was the encapsulation of fluorescent molecules. As
described before, liposomes are easily manipulated, nearly omniphilic for possible
encapsulations, and as such, membrane anchored antibodies and proteins with high
affinities can and have been incorporated which bind molecules/proteins of interest.
This has led to the semi-cascade strategy of binding ligands and fluorophores leading
to amplification of endogenous ligand bound to protein.

Imaging:
Liposomal imaging has also benefited from the introduction of radionuclides 99mTc,
67

Ga, and 111In.50 A cholesterol heavy diagnostic liposome using 111In, Vescan®, is

used for imaging melanoma, sarcoma, and lymphoma tumors with high specificity and
sensitivity. The radionuclides require significant stabilization, using such water
soluble chelators, deferoxamine (DF) and nitriloacetic acid (NTA). Lipid anchored
chelation exists as well, a product of stearylamine (SA) or phosphoethanolamine (PE)
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with diethylene triamine pentaacetic acid (DTPA). Signal intensity has been increased
with polychelating amphiphilic polymers (PAPs).

EPR effect:
Unilamellar vesicles can exhibit a variety of sizes, with a lower limit of 20 nm, in
terms drug delivery, they are referred to as nanomedicines. This class size of medicine
exhibits a special effect on tumors due to their tumultuous growth, known as the
enhanced permeability and retention effect (EPR).55,57 This phenomenon occurs when
tumors become large enough to require and develop their own blood supply. Unlike
non tumorous blood vessels and biological infrastructure, tumors provide a crude
framework with large gaps between capillary endothelium and afford poor lymphatic
drainage. Poor drainage and gaps improve the retention of large particles like
liposomes, engaging in EPR in a passive fashion. The gap between endothelium and
interstitial space is normally 5-10 nm, while tumors possess gaps upwards of 100-780
nm, allowing a multitude of larger particles and macromolecules to aggregate.57 Even
though non targeting nanomedicines rely on EPR to aggregate and have its most
potent effect, liposomes are still the target of the reticuloendothelial system (RES),
which uptakes particles, including vesicles, before the liposome can enter the
tumorous cell. A suggested size limit for drug delivery vehicles is ~400 nm for highest
uptake. To semi-solve this problem, stealth liposomes have been developed, the
introduction of PEG to the vesicles affords a large shell of water around the particle,
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blinding it from RES.58 This however also has inherent complications, because
endocytosis into the cell of interest becomes more difficult.

Todays chemotherapeutics are highly toxic and efficiently destroy cancerous cells, yet
pose a serious danger to the effected, the drugs themselves afford the most danger
from their inherent activity. Which is why tissue and cellular targeting is so important,
accuracy is nothing without precision, a drug is only effective if it only does its
assigned ‘job’. Fortunately, the maligned tissue offers a solution, tumor vasculature
affords defective endothelial cells, wide lumen, lymphatics, and lack smooth muscle,
all of which allows particles of a certain size range to potentially aggregate around the
tissues, with gaps up to 4 μm in size. The effect is time dependent, the more time
allowed to circulate through the blood, the higher the near-tumor concentration of
particles. Renal excretion is inhibited, also due to size, prolonging the life of nanodrugs and relaying a difference on concentration of up to ten times compared to small
molecular weight drugs.

Functionalization:
Multifunctional liposomes up the ante with a variety of triggers and ligands, able to
direct themselves to the target and perform any number of functions. Cleavable PEG
nearly perfects the usage of PEGylated liposomes, having the ability to remove PEG
through simple hydrolysis of the ester linkage by esterases or low pH.58
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Targeting of liposomes is an exceptional technique, using covalently bonded ligands
and or antibodies anchored to the vesicle, and is a common strategy for tumors and
cancers as many exhibit over expressed receptors on the membrane surface.

Some of the most studied and important targets known in cancer to date are associated
with membrane proteins and exhibit uptake mechanisms, including folate/folate
receptor, transferrin/transferrin receptor, integrins, and human epidermal growth
factor. These species have shown great promise in reverse oncogenesis.

Transferrin Receptor targeting:
Transferrin receptor is known to be upregulated in many cancerous cell lines, with an
ability to cross the blood-brain barrier delivering anti-cancer medicines.59 Covalent
linkage to transferrin has improved uptake of chemotherapeutics and a selective
increase in cytotoxicity. Drug-resistant lines have also been shown to uptake
transferrin-bound drugs, halting their developed response to counteraction.
Transferrin functions as a serum iron transport protein, 78 kDa glycoprotein, binding
up to two Fe3+ at a time, with a binding affinity higher than that of avidin/biotin, with a
constant upwards of 1022 M-1 at pH 7.4. As transferrin binds iron cation, a
conformational change results, leading to a higher affinity for its receptor, transferrin
receptor, with the diferric transferrin having upwards of a 100-fold increase in affinity
compared to apotransferrin (non ferric binding transferrin).
Transferrin receptor levels are expressed higher on cells which proliferate more
frequently, especially cancerous cells. The ferric transport proton has also become a
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highly studied target for anticancer research purposes. Transferrin is also the main
peptide used in the transportation of iron into the brain, as well as the passage of
transferrin and anti-transferrin antibodies into the brain.

4.3 Immunoliposomes

Immunoliposomes are formulated by attaching antibodies to the surface, allowing
targeting to cancerous cells.49,52,54,56 The vesicles have been developed in three
different ways: type 1a exhibits antibodies bound to the bilayer; type 1b employ
PEGylated liposomes with antibodies both attached to the bilayer; type II use
PEGylated liposomes which have the antibodies covalently attached to the end of
PEG.

Figure 4.3. The three types of immunoliposome variations. Type 1a in the image uses single-chain
variable fragment (scFv) in place of the entire antibody.

Single-chain variable fragments (scFv) are fusion proteins which exhibit the smallest
possible amino acid sequence containing the antigen binding site. scFv have been
favored recently not only to their smaller size, but their formation from genetic
engineering, easily allowing various amino acids to couple to the bilayer, in particular,
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cysteine is generally used to replace a maleimide. Whole antibody liposomes have the
unfortunate problem of immunogenicity, being able to be taken up by macrophages
and certain liver cells, while scFv liposomes do not have this concern.

For the enhancement of a fluorescent response from the acetylcholine conjugate to
visibly mark the nAChR through confocal microscopy, we chose the encapsulation of
water soluble dyes with unilamellar vesicles at concentrations which can provide up to
thousands of times the brightness of a single bound molecule depending on
concentration of the encapsulated liposome.

We chose to use 400 nm as a suitable size for liposomes, determining whether or not
the anchored cyclen can sufficiently bind to PTS with such a large surface area in such
close proximity. Cyclen 1 was anchored to the bilayer through the introduction of a
palmitoyl side chain. As cyclen itself is not soluble in aqueous media, we hypothesize
the ‘arms’ of cyclen 1 are flattened out over the phosphate heads, giving a π-cation
interaction. This seems reasonable as the anisole derivative arm structure is similar to
tyrosine, which exudes a π-cation interaction with ammonium group of acetylcholine
in the binding pocket of nAChRs. The free liposome’s random movement through
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solvent, will, upon close proximity to a bound ACh-PTS, bind tightly and anchor the
liposome ‘above’ the nAChR, yielding a high fluorescent emission with light.

Figure 4.4. Image depicting the cascade binding sequences between a Protein of Interest (blue, bright
blue active site), ligand-fluorophore derivative (green), and a liposome anchored with cyclen-1 (red).
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CHAPTER FIVE

Synthesis of ACh derivatives and liposome encapsulation

5.1 Introduction

Possessing the technology to bind a fluorescent, membrane impermeable, small
molecule affords the ability to develop a multitude of assays and investigations to
better improve biological knowledge and quality of life. The decision to invent a small
molecule director, for the use in excisional biopsies and procedures was/is being
pursued. Methodology is crucial, and as such, the following new molecules and
studies should offer a new strategy for the fluorescent visualization of tissues of
interest i.e. malignant tissue/tumors. As nAChRs are so important in a variety of
diseases and neurological disorders, compounded with the fact that nAChRs are some
of the most studied receptors to date, we decided to use the protein as the foundation
for ligand gated ion channel labeling and subsequent amplification.

The labeling molecule should possess similar receptor affinity and share as much
structural integrity as possible. Therefore, a derivative of the endogenous ligand,
acetylcholine, was synthesized with the intention for biological labeling activity. Since
various studies throughout the years point out the fact that the trimethylammonium
‘head’ of acetylcholine is near perfected and is farthest into the receptor cavity, this
moiety was preserved. The moiety chosen to alter was the acetate group, as many
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different ligands have been synthesized based off this and does not inhibit
functionality like the trimethylammonium head.

Figure 5.1. Acetylcholine, endogenous ligand of nAChRs, base molecule

5.2 Synthesis of Acetylcholine pentynoate. And Beyond.

Since the acetate tail of acetylcholine can be functionalized with minimal binding
interference, to a pyrene trisulfonate, we decided to create a derivative of
acetylcholine which possesses a terminal alkyne, to perform click chemistry. Using
click chemistry requires an azido partner to couple with, as such, azidopyrene
trisulfonate was first synthesized by Dr. Hartman in 2013 and was chosen as the
second half of the heterosandwich molecule.
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Scheme 5.1. Synthetic scheme of choline pentynoate and AChPTS. Choline pentynoate (first
sequence).

4-pentynoic acid was added to a flame dried flask and potassium bicarbonate was
added. The solids were dissolved in 200 μL of dry DMSO and stirred for 30 minutes.
5 equivalents of bromocholine bromide was dissolved in 1.2 mL DMSO and added to
the flask under vigorous stirring at 50ºC for 30 hours. It is noted that temperatures
below 50ºC afforded no reaction and temperatures above 50ºC suffered heavy
decomposition byproducts. Optimized reaction conditions were created through
systematic treatment of the above compounds through various degrees of heating and
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time, ultimately leading to the high number of equivalents of bromocholine bromide
used. The use of AgO or AgCO3 did not improve the yield but actually inhibited the
reaction from moving forward. Silica gel column chromatography of gradient
chloroform/methanol mixture lead to 134 mg of 2-(trimethylammonium)ethyl pent-4ynoate (referred to as choline pentynoate).

The use of click chemistry made the process quite efficient, as the click partner (azide)
of pyrene trisulfonate was first synthesized in 2013 by Matthew C.T. Hartman, 8azidopyrene 1,3,6-pyrenetrisulfonate using Sandmeyer conditions with APTS, a
cyclen-1 binding dye.2

Scheme 5.2. AzidoPyrene synthesis as described by Dr. Matt Hartman.

Azidopyrene trisulfonate was dissolved in water in a foil wrapped round bottom flask,
copper sulfate and sodium ascorbate were added and stirred for ten minutes. Choline
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pentynoate was dissolved in water and added to the solution. The mixture was stirred
for 18 hours at 45ºC to afford the desired click product:

Along with the new ACh-fluorophore, cyclen-1 itself can only perform so much
function. However, with the introduction of cyclen-1 into a trojan horse fluorophoric
vehicle, the ability to enhance the fluorescence response up to thousands of times may
be possible.

Figure 5.2. Cyclen-1 with functionalization possibilities with toluidyl moiety.

Manipulating the toluidyl moiety of cyclen-1, one can perform many chemistries,
converting the aromatic amine into an amide, sulfonamide, urea, secondary amine,
azide, carbamate etc. For our purposes, we chose amide formation with palmitoyl
chloride, in order to envelope the cyclen molecule in the lipid bilayer of liposomes.
Palmitoyl chloride is extremely reactive and possesses a relatively low boiling point
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(88℃), leading to easy purification and reaction conditions. It was hypothesized the
long acyl chain would distribute itself among EYPC lipid tails, with the polar cyclen
arms at the forefront of phase change.

Scheme 5.3. Reaction of cyclen-1 with palmitoyl chloride. Relative sizes are exaggerated for clarity of
reactive group in reference.

Liposomes:
For the enhancement of a fluorescent response from the acetylcholine conjugate to
visibly mark the nAChR through confocal microscopy, we chose the encapsulation of
water soluble dyes with unilamellar vesicles at concentrations which will provide up
to one million times the brightness of a single bound molecule. Unilamellar vesicles
are particles made with molecules containing a hydrophilic ‘head’ and hydrophobic
‘tail’. In aqueous environment, the tails coalesce together and form a bilayer, similar
to the biomembrane, with the hydrophilic heads on the interior and exterior, forming
more favorable interactions with the solvent, water, including an aqueous core.
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In this study, the unilamellar vesicle of choice are liposomes. Liposomes consist
primarily of phospholipids, amphipathic molecules with an anionic glycerophosphate
head. Liposomes have the ability to encapsulate a variety of molecules, hydrophilic, in
the aqueous core, and hydrophobic molecules, within the lipid bilayer. Drugs have
been encapsulated in liposomes to a great degree of success, as the liposomal
doxorubicin improves efficacy and stability. As most unilamellar liposomal
preparations are between 20 nm and 1 μm, the ‘solution’ is in reality a colloid.

We chose to use 400 nm as a suitable size for liposomes, determining whether or not
the anchored cyclen can sufficiently bind to PTS with such a large surface area in such
close proximity. Cyclen 1 was anchored to the bilayer through the introduction of a
palmitoyl side chain. As cyclen itself is not soluble in aqueous media, we hypothesize
the ‘arms’ of cyclen 1 are flattened out over the phosphate heads, giving a π-cation
interaction. This seems reasonable as the anisole derivative arm structure is similar to
tyrosine, which exhudes a π-cation interaction with ammonium group of acetylcholine
in the binding pocket of nAChRs. The free liposome’s random movement through
solvent, will, upon close proximity to a bound ACh-PTS, bind tightly and anchor the
liposome ‘above’ the nAChR, yielding a high fluorescent emission with light.

Phosphatidylcholine liposomes were prepared from egg yolk phosphatidylcholine
(EYPC), 400 nm membrane through membrane extrusion conditions. Rhodamine B, a
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water soluble, high emission dye in the high visible spectrum (red), was chosen as the
indicative fluorescent marker to be used in the aqueous core of EYPC liposomes.

Figure 5.3. Structure of Rhodamine B.

400 nm Cyclen-2 anchored liposomes were produced through 1.5% cyclen-2 in EYPC
dissolved in 190 proof ethanol. Solvents were extricated via overnight oil pump
evaporation. The mixture was hydrated with 50 nM Rhodamine B PBS buffer (2mL),
pH 7.4 and 5 freeze/thaw cycles were performed, ensuring maximum containment.
Extrusion through 400 nm membrane 21x lead to uniform vesicles which were
purified through a Sephadex G-10 size exclusion column leading to a light purple
milky solution (1.7mL) of cyclen-2 anchored 50nM Rhodamine B liposomes.

100 nm cyclen-2 anchored liposomes with 50 nM encapsulated Rhodamine B were
made identically to 400 nm liposomes (the smaller 100 nm membrane was used for
extrusion).
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Figure 5.4. Image describing cyclen anchored liposome, with binding event of AChPTS. Pink
sphere represents the liposome, orange elongated ‘U’ shows the cyclen receptor and the green
shape shows AChPTS dye.
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CHAPTER SIX

in vitro Assay of AChPTS with HEK-293 and Endothelial cell lines
6.1 Introduction
HEK-293 cells within the following studies over express nAChRs on the cell surface,
more easily allowing establishment of our hypothesis. With the assay examining the
binding of ACh-PTS to the membrane, along with the hypothesized cyclen anchored
liposomes, the following steps include the in vitro introduction of ligand conjugated
dye in the presence of different cell types, testing the hypothesis to an extent whether
or not the acetylcholine conjugate can target cells of interest as designed. The coculture of endothelial cells and previous assay will be performed, gaining insight into
whether or not the acetylcholine conjugate somehow recognizes the new cells as a
target.
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6.2 HEK-293 binding assay with AChPTS and liposome

The first assay begins with a positive test for binding through visualization with
fluorescence microscopy. If the ACh conjugate acts as an agonist/antagonist, the cells
should be visibly ‘green’ with fluorescent molecules, indicative of binding.

The first trial shows promising results for the methodology. Green fluorescence can be
noticed around the edges of cells, allowing for the continuation of the study (image
B).
The overlap image produces a much better visualization of binding of the ACh
conjugate (image C). Notice the blue arrows highlighting an increase in signal, located
in one specific area of the cells. nAChRs, and most membrane proteins are thought to
distribute themselves almost evenly throughout the membrane, however, these seem to
aggregate in a certain manner. This phenomena could also be due to the nature of
HEK cells themselves, as we know nAChRs at the neuromuscular junction are
throughout the cell, ‘lining up’ to afford a cascade mechanism of cellular polarization.
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Figure 6.1. First assay of over expressing nAChR HEK-293
cells. Bright field image of HEK-293 cells, image A. The
introduction of 50 nM AChPTS dye after a five minute
incubation, fluorescent mode, image B. Overlay of bright
field and fluoro modes, image C, arrows indicate
aggregation of nAChRs. Image D shows the incubation with
400 nM liposomes (encapsulated with Rhodamine B). Image
E, overlay of A & D.
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Concentration-dependent aggregation of liposomes (images D & E) upon the slide
make it somewhat more difficult to gauge, however, noticing the same areas where
green fluorescence is localized, shows binding of liposomes to the AChPTS bound to
nAChRs on the membrane.

6.3 HEK-293/Endothelial co-culture binding assay with AChPTS and liposomes

The co-culture with endothelial cells is used as a control experiment, determining
whether or not AChPTS preferentially binds with HEK-293 nAChR expressing cells,
while endothelial cells do not bind the fluorescent marker.

Image F shows endothelial cells (elongated and ‘flat’) with HEK-293 cells
(round/circular). Notice all HEK-293 cells exhibiting fluorescence. Only a couple
endothelial cells seem to bind/aggregate the dye (cyan arrows). The rest of the cells
fluorescing are most likely the HEK-293 line (image H).
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Figure 6.2.HEK-293 and endothelial cell co-culture, bright
field, image F. 50 nM AChPTS after a five minute
incubation, image G. Overlay of F & G, image H. Blue
arrows suggest labeled endothelial cells. Image I describes
co-fluorescence of AChPTS and liposomes, Image J shows
total liposomal fluorescence after AChPTS quench.
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This image more clearly indicates HEK-cells exhibiting a fluorescent signal.
Interesting is the co-fluorescence of both dyes in image I, AChPTS (green)

and Rhodamine B (red). The endothelial cells in the foreground do not seem to show
any fluorescence after a wash. As with previous images of HEK cells, these again
afford a localized pattern of nAChR aggregation (cyan arrows).

A stoichiometry determination between liposomes and AChPTS was made using the
culture in images I & J. In image I, cells were incubated for five minutes each with
100 nM AChPTS and then 50 nM Rhodamine B liposomes before imaging. A titration
with liposomes was performed, until all green fluorescence (from AChPTS) was
quenched. Image J shows 120 nM liposomes were sufficient to fully quench green
fluorescence, determining a ~1:1 (120nM:100nM) binding ratio between liposomes
and AChPTS.

An upper limit of fluorophore concentration was determined to be ~200 nM AChPTS
and 200 nM liposomes. Images L and M show a high level of labeling/fluorescent
signal on the cell cluster.
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Figure 6.3. Cluster of HEK-293 and endothelial cells,
image K. 200 nM AChPTS incubation, image L. After
addition of 200 nM liposomes, image M is formed.
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6.4 Methodology

Using this assay as a stepping stone, we can assume from the following results that 1)
binding of AChPTS is successful, 2) cyclen anchored liposomes behave as predicted
and sufficiently bind the pyrene molecule, 3) fluorophore encapsulated liposomes help
improve visualization 4) kinetics of both binding events are extremely quick, leading
to a powerful message.

Excision technology:
Excision technology could be modified to use the methodology exploiting the
interactions based on the cyclen/pyrene system. A visible detection method and sight
directed procedure could greatly increase the precision compared to the current form,
using a variety of diagnostics before and after surgery on the affected area (PET,
FISH, immunohistochemistry, flow cytometry, CT scan, MRI, etc.). Since the
methodology uses nontoxic substrates and fast identification, assistance with the
physical detachment of tissues should be greatly improved.

The fluorescent tagging of excision able tissue can arise from the derivitization of a
receptor ligand or antibody for the cell type. Using an HPTS core fluorophore attached
to the cell identifiable ligand should behave as similarly as the cell studies performed
in this work. The subsequent addition of encapsulated vesicles should heighten the
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visible response and improve cellular differentiation, leading to a more sophisticated
technique and proper removal of malignant tissues.

Using a sight directed aid, as described, will help reduce the invasiveness of the
procedure, limiting exposure and lead to faster healing. The use of fluorescent media
in medical procedures has minimal current study, and has been investigated somewhat
using radiotracers, allowing a new type of methodology to expand the bounds of
patient care.
Identification and localization of malignant tissue is imperative in the operative
removal of the mass of cells (excision).

Figure 6.4. Depiction of envisioned excision using cyclen-pyrene technology with fluorescent
amplification.

Neoplasms are generally targets for excisional biopsies and excisional operations, as
the abnormal growths need to be tested for cancer as well as other skin diseases. Basal
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and squamous cell carcinomas are known to behave in a manner which limit their full
detection, requiring methods to observe the delineation between cell types.
Microscopic excision technology is one the most successful methods of eliminating
malignant tissue from the body with physical means. Determining the physical edge of
harmful tissues thus requires a more sophisticated approach, delivering a visible
identifier/tag to the area.
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CHAPTER SEVEN

Future Work

7.1 Introduction

Using our first assay used as a stepping stone for a new methodology has been
successful. The modified endogenous ligand has shown to bind nAChRs along with
the binding of the cyclen-1 anchored liposomes, reaching visual acuity.

7.2 Stronger binding models for the nAChR system

Even though acetylcholine is the endogenous substance for nAChRs, more potent
species are available; nicotine, nicotine derivatives, and �-Bgtx are examples of
possible molecules for applicable assays.

The cholinergic hypothesis of the onset of depression describes the hyperactivity of
nicotinic receptors of the cholinergic system, compared to a hyperactive adrenergic
system within the brain. As cholinergic receptors are overactive, levels of choline and
hence acethylcholine are unregulated in depression brains. Since nicotinic receptors
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are affected versus muscarinic, highly selective nAChR agonists and antagonists need
to be used for study. One example is a derivative of nicotine, S1B-1508Y:

Figure 7.1. Synthetic nicotine derivative, S1B-1508Y

The only difference between this molecule and nicotine itself is the ethynyl moiety,
yet possesses 1000 fold potency in receptor activation.31

Scheme 7.1. Possible synthetic scheme of SIB/AzPTS conjugate
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As shown above in the scheme, an additional acetylene moiety is installed, this is so
click chemistry can be performed, extending the range of this synthetic derivative with
high affinity. The additional acetylene group can be added via the one step Cadiot–
Chodkiewicz coupling reaction, or Glaser coupling with trimethylsilylacetylene.

The highest binding natural substrate, �-Bungarotoxin, can be conjugated to pyrene
dye in the same manner. A suggested model is the following, pentynoic acid
conjugated to ε-N of Lysine, which can be added to the N- or C- terminal of the
peptide.

Figure 7.2. AzPTS-Bgtx derivative

7.3 Pyrene based system for various coupling reactions using SuFEx

chemistry

Sulfur(VI) Fluoride Exchange (SuFEx) chemistry has early roots, however, its
grandiose in becoming an extremely powerful coupling methodology is due to Dr.
Barry Sharpless in the past year.60 His extensive work shows the ability for a new
“click chemistry”, wide in scope, high yields, low impact, and easily purified products.
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Palladium cross couplings with sulfonyl fluoride, as a replacement for triflate, easily
accessible sulfonamides, sulfates, polymers, and more. SuFEx employs the use of a
cheap, highly produced gas, Sulfuryl Fluoride, SO2F2, and a molecule dubbed “the
most perfect Michael acceptor ever found”, H2C=CHSO2F, ethenesulfonyl fluoride
(ESF).61 Since the sulfur fluoride bond of sulfonyl fluorides is quite strong, the
coupling is specific, using certain conditions depending on the chemistry wanted.
Unlike sulfuryl and sulfonyl chlorides, the fluorides are extremely stable,
decomposition and side reactions are eliminated, as well as the ability to better control
the reaction.

Scheme 7.2. Ligation methods of HPTS using SuFEx chemistry.

The fluorosulfates (R-OSO2F) can act as a replacement for the triflate group (OTf) and
can also be used in palladium cross coupling reactions i.e. Suzuki, Heck, Sonogashira,
enhancing the amount of chemistry the pyrene trisulfonates previously exhibited.
Another extension, in scope and connection is the use of ESF, with the Michael
addition being quick with generally 100% conversion of nucleophile, allowing the
sulfonyl fluoride to react with another partner, possibly enzymes.
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General polymerizations:

The employment of pyrene trisulfonates and pyrene tetrasulfonate in polymerizations
can be possible with the new chemistries available. A four way sulfonyl linker can be
afforded easily using the demonstrated transformation.

Scheme 7.3. Scheme of PTA being polymerized via SuFEx.

Using polymerization partners like diamines or diols, large net-like polymers, MOFs,
and possibly dendrimers could be synthesized easily from affordable and accessible
starting materials.
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EXPERIMENTAL SECTION

All chemicals and solvents were purchased from either Sigma-Aldrich, Acros
Organics or Fisher Scientific and used without further purification. Column
chromatography was performed with silica gel 60 (230-400 mesh). All 1H NMR
spectra were recorded on a Varian 300 MHz NMR spectrometer. All NMR chemical
shifts (δ) were reported in parts per million (ppm) and were determined relative to the
standard values for deuterated solvents.

2-(trimethylammonium)ethyl pent-4-ynoate: 4-Pentynoic acid (100 mg, 1mmol)
and potassium bicarbonate (140 mg, 1 mmol) were dissolved in 200 μL of DMSO and
stirred for 30 minutes. 2-(bromoethyl) trimethylammonium bromide (1.26 g, 5 mmol)
was dissolved in 1.2 mL DMSO and the two solutions were combined and stirred at
50ºC for 30 hours. The solvent was concentrated under reduced pressure. The crude
solid was purified via column chromatography, (silica gel, gradient CHCl3/MeOH 8:14:1) to give 134 mg (0.507 mmol, 51%) of product. 1H NMR (300 MHz, DMSO) δ
3.44 (m, 1H); 3.15 (s, 9H); 2.51 (m, 2H); 2.31 (ddt, J= 9.5, 6.9, 1.5 Hz, 2H); 2.18 (td,
J= 7.5, 7.1, 1.6 Hz, 2H); 1.22 (s, 2H). ESI-MS calc’d for C10H18NO2+ (M+) 184.13;
found 183.403.

8-(4-(3-(2-(trimethylammonium)ethoxy)-3-oxopropyl)-1H-1,2,3-triazol-1yl)pyrene-1,3,6-trisulfonic acid triammonium salt: 2-(trimethylammonium)ethyl
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pent-4-ynoate (35 mg, 0.13 mmol), 8-azidopyrene-1,3,6-trisulfonic acid triammonium
salt (12 mg, 0.05 mmol), copper sulfate (0.2 mg, 0.001 mmol), and sodium ascorbate
(0.15 mg, 0.002 mmol) were dissolved in 2 mL millipore water and stirred for 18
hours at 45ºC in the absence of light. The crude reaction was then purified by sizeexclusion chromatography to afford 16 mg pure product (0.05 mmol). 1H NMR (300
MHz, D2O) δ 9.36-9.25 (m, 1H); 9.29 (s, 2H); 9.22-9.07 (m, 1H); 8.70 (s, 1H); 8.19 (s,
1H); 7.93 (d, J= 9.7 Hz, 1H); 3.16 (t, J= 0.9 Hz, 9H); 2.90-2.69 (m, 2H); 2.57 (t, J=
7.3 Hz, 2H); 2.49-2.38 (m, 2H); 2.36-2.29 (m, 2H). ESI-MS calc’d for (M2+) 332.03;
found 332.23.
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